Adaptimmune Therapeutics plc (473A) — Financial Flexibility Index
Adaptimmune Therapeutics plc (473A) has a Financial Flexibility Index of -0.17x as of June 2025. Free cash flow of €-34.70 Million (operating CF €-34.78 Million minus capex €75.00K) represents 0% of total liabilities (€201.59 Million). Also explore Adaptimmune Therapeutics plc (473A) net asset momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Adaptimmune Therapeutics plc Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Adaptimmune Therapeutics plc across 9 annual periods. Check Adaptimmune Therapeutics plc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Adaptimmune Therapeutics plc (2016–2024)
Year-by-year free cash flow to debt coverage for Adaptimmune Therapeutics plc. For the full company profile including market capitalisation, see 473A market cap overview.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.30x | €-70.49 Million | €-73.21 Million | €234.11 Million | ▲ +46.2% |
| 2023 | -0.56x | €-136.00 Million | €-140.88 Million | €243.10 Million | ▼ -23.1% |
| 2022 | -0.45x | €-112.27 Million | €-141.77 Million | €247.04 Million | ▼ -720.6% |
| 2021 | 0.07x | €19.30 Million | €10.73 Million | €263.58 Million | ▲ +115.7% |
| 2020 | -0.47x | €-51.25 Million | €-53.59 Million | €109.92 Million | ▲ +75.7% |
| 2019 | -1.92x | €-110.92 Million | €-112.51 Million | €57.91 Million | ▲ +43.1% |
| 2018 | -3.37x | €-100.48 Million | €-104.39 Million | €29.85 Million | ▼ -786.7% |
| 2017 | -0.38x | €-29.67 Million | €-54.31 Million | €78.16 Million | ▲ +26.6% |
| 2016 | -0.52x | €-35.38 Million | €-48.17 Million | €68.37 Million | — |